C43.9
Conditions
Interventions
Group 1: patients with malignant melanoma stage IIB-III (n= 500)
Sponsors
Universitätsmedizin Göttingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Presence of malignant melanoma in AJCC stage IIB, IIC, IIIA, IIIB, IIIC or IIID - Diagnosis made within the last 5 years or stage transition to one of the aforementioned stages within the last 5 years - Age =18 years - Adjuvant therapy situation, but independent of current or previous therapy - Ability to understand the Discrete Choice Experiments - Capacity to consent - Written consent to participate in the study
Exclusion criteria
Exclusion criteria: Excluded from participating the study are the investigators themselves and members of the study team who directly or indirectly participate in conducting the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of the clincal study is the patients' preferences for the different options of adjuvant therapy based on the attributes that are captured in the questionnaire. These attributes include the risk of recurrence within a year, typical adverse effects, the risk of severe adverse effects, that impair well-being severly or longterm or require hospitalization, as well as application form and frequency of the treatment (oral therapy vs. intravenous infusions). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is the investigation of sociodemographic, socioeconomic and clinical characterics that may influence the patients' preferences for adjuvant therapy. Especially the relevance of age, sex, education, income, disease-related characteristics and comorbidities for the decision-making process will be discussed. | — |
Countries
Germany
Contacts
Public ContactChristian Kromer
Universitätsmedizin Göttingen
Outcome results
None listed